Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osaka prospective cohort study of COVID-19 vaccine effectiveness and safety
jRCT1051200143Completed
- Start
- Mar 2021
- Countries
- 1
01
Overview
Open-label, single-arm trial in coronavirus disease 2019 (COVID-19). Primary endpoint: Immunogenicity: antibody response against SARS-CoV-2 spike protein. Started Mar 2021; status: completed.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT1051200143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051200143.